Henkel AG & Co KGaA (HELKF) Q4 2024 Earnings Call Highlights: Record Gross Margin and ...
Organic Sales Growth: 2.6% for the group; Adhesive Technologies at 2.4%; Consumer Brands at 3%.
Gross Margin: 50.6%, highest in over 30 years, up nearly 500 basis points from the previous year.
Adjusted EBIT Margin: 14.3%, an increase of 240 basis points from the previous year.
Free Cash Flow: EUR 2.4 billion.
Adjusted EPS Growth: 25% increase at constant currencies.
Dividend Proposal: 10% increase to EUR 2.04 per preferred share.
Share Buyback: Up to EUR 1 billion announced.
Net Financial Position: Minus EUR 93 million.
Adhesive Technologies Sales: EUR 11 billion with an adjusted EBIT margin of 16.6%.
Consumer Brands Sales: EUR 10.5 billion with an adjusted EBIT margin of 13.6%.
Portfolio Optimization Savings: EUR 525 million expected by year-end.
Warning! GuruFocus has detected 7 Warning Signs with HELKF.
Release Date: March 11, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Henkel AG & Co KGaA (HELKF) delivered strong top and bottom line performance in 2024, with organic sales growth of 2.6%.
The company achieved the highest gross margin in over 30 years at 50.6%, with significant improvements in both Consumer Brands and Adhesive Technologies.
Henkel successfully concluded its portfolio optimization measures ahead of schedule, achieving targeted savings of EUR 525 million by the end of 2024.
The company reported a strong free cash flow of EUR 2.4 billion and a 25% increase in adjusted EPS, leading to a proposed 10% dividend increase and a new share buyback plan.
Henkel's Consumer Brands business saw strong growth, particularly in hair care, and the company is confident in further top and bottom line growth for 2025 despite a challenging environment.
Henkel's North American market faced challenges, with both business units experiencing a year-on-year decline due to a challenging industrial market environment.
The company anticipates a slower start to 2025, with subdued market growth in Q1 and high prior year comparables impacting performance.
Henkel's Adhesive Technologies business experienced a softer Q4, particularly in the automotive segment, impacting overall performance.
The company faces ongoing volatility and uncertainty in the macroeconomic and geopolitical environment, which could impact future performance.
Henkel's Consumer Brands business is dealing with nonrecurring operational challenges related to supply chain optimization, affecting Q1 2025 performance.
Q: Can you elaborate on the first quarter guidance and the impact of one-off disruptions and promotional activities? Are there any delistings due to pricing strategies? A: The slower start in Consumer Brands is due to high comparables from early 2024 innovations, a softer market, particularly in the US, and nonrecurring one-offs related to the 1-1-1 approach. There are no delistings due to pricing strategies, but some destocking by retailers has impacted volumes. We expect an acceleration in H2, supporting our 1% to 3% growth guidance for 2025. Carsten Knobel, CEO
Q: What caused the sequential growth decline in Adhesives in Q4, and what are the expectations for 2025? A: The decline was mainly due to a softening in the industrial markets, particularly automotive, and a downgrade in the IPX index. However, electronics performed well, and we expect 2% to 4% growth in 2025, with stronger performance in H2. Carsten Knobel, CEO
Q: How has demand in key customer industries for Adhesives held up in Q1, and what is the outlook for Consumer Brands? A: Adhesives are experiencing a softer market, particularly in North America, but we are outperforming the market. In Consumer Brands, we expect stronger performance in H2 due to innovation launches and the conclusion of portfolio measures. Carsten Knobel, CEO
Q: With gross margins at all-time highs, why is the gap between gross and EBIT margins increasing? A: We have increased investments in marketing and advertising to support brand equity and top-line growth, which impacts SG&A expenses. Despite divestments, we are focusing on innovation and brand support. Marco Swoboda, CFO
Q: Could Adhesives benefit from increased European defense and infrastructure spending? A: While Germany is not a major market for us, increased spending could positively impact our Adhesives business, particularly in defense-related applications. Carsten Knobel, CEO
Q: Was there any market share loss or repricing event in Adhesives in Q4, and what is the outlook for 2025? A: There was no significant market share loss or repricing event. We expect to outperform the market in 2025, driven by positive volumes and robust pricing, particularly in electric vehicles and electronics. Carsten Knobel, CEO
Q: What factors contribute to the expected stronger performance in H2 for Consumer Brands? A: The stronger H2 is expected due to a more pronounced innovation pipeline, nonrecurring operational impacts being resolved, and the positive impact of portfolio measures. Carsten Knobel, CEO
Q: What is the outlook for free cash flow and M&A opportunities in 2025? A: We expect free cash flow to remain strong, above EUR2 billion, supporting potential M&A opportunities in both business units. We are confident in our financial foundation to pursue attractive acquisitions. Marco Swoboda, CFO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
BharCap Partners Closes Oversubscribed Fund II at $652 Million
Fund II targets management buyouts of asset-light financial services businesses GREENWICH, Conn., June 09, 2025--(BUSINESS WIRE)--BharCap Partners, LLC ("BharCap"), a private equity firm focused on the financial services sector, today announced the final closing of its second fund, BharCap Partners Fund II, LP ("Fund II"). Fund II was oversubscribed with $652 million in equity capital commitments, 30% above its $500 million target. BharCap has raised over $1.1 billion of committed equity capital through Fund II and affiliated co-investment vehicles. BharCap is led by founding partners Bharath Srikrishnan, Ethan Wang, Jim Rutherfurd, Kevin Becker and Ryan Gean. Bharath Srikrishnan, Co-Founder and Managing Partner, said, "First and foremost, I would like to thank everyone who has supported us on this four-year journey. We created BharCap because we believe entrepreneurs in our sector would benefit from a new firm with a distinctive approach. We are highly entrepreneurial professionals who are sector specialists. We have unique operational and strategic capabilities. Our 'Entrepreneurs Backing Entrepreneurs' mantra resonates with management teams. We believe this fundraise demonstrates our differentiated value proposition, the quality and depth of our team and the attractiveness of our sector. With 27 professionals and operating advisors and substantial dry powder, we are well positioned to identify and support outstanding management teams." The fund's closing marks a pivotal moment as BharCap continues to source unique investment opportunities which leverage the firm's longstanding relationships with entrepreneurs. BharCap's Fund II targets management buyouts in asset-light middle-market financial services companies. Our focused sub-sectors include wealth and asset management, insurance distribution and insurance services, financial technology and tech-enabled financial services, and tax, accounting and advisory services. BharCap focuses on companies with recurring revenue, strong profit margins and high free cash flow conversion that we can scale. We seek to invest alongside management teams to capitalize on powerful long-term growth trends, sub-consolidation opportunities in highly fragmented markets and the impact of technological advancement. Fund II and its LP co-investment vehicles typically invest $50 to $300 million in North American companies with EBITDA of $10 to $50 million. Ethan Wang, Co-Founder and Partner, said, "With our entrepreneur-centric approach and deep sector expertise, we provide the tools that financial services companies need to succeed. We have a robust pipeline of proprietary investment opportunities sourced by our proactive, outbound calling effort. We are excited to originate new investment opportunities, drive continued success for our portfolio companies and create significant value for our limited partners and management teams." Fund II's investors are a diverse group of limited partners from North America, Europe and Asia, including insurance companies, asset managers, public pension plans, institutional consultants, endowments and foundations, high-net-worth individuals and family offices. Jim Rutherfurd, Co-Founder, Partner and Head of Investor Relations, said, "We are grateful for and honored by the support from our limited partners, particularly considering the impact of economic and geopolitical uncertainty on the fundraising environment. Our LP base includes some of the most prominent and well-regarded fund investors. Fund II has significant embedded value, and we are highly focused on extending our track record of outstanding asset light financial services investments." Fund II has invested approximately 30% of the Fund in four portfolio companies in the insurance brokerage, insurance services, payment processing and wealth management sectors. For further inquiries or partnership opportunities, please contact Jim Rutherfurd at jim@ Rede Partners served as placement agent and Kirkland & Ellis served as fund formation legal counsel to BharCap Fund II. About BharCap Partners:BharCap Partners, LLC invests in businesses across the financial services industry including wealth and asset management, insurance distribution and insurance services, financial technology and tech-enabled financial services, and tax, accounting and advisory services. BharCap manages over $2 billion of capital. For more information, please visit View source version on Contacts Media Contacts:Delia Cannan / Pamela GreeneReevemark212-433-4600BharCapPartnersTeam@ Sign in to access your portfolio
Business Wire
3 hours ago
- Business Wire
BharCap Partners Closes Oversubscribed Fund II at $652 Million
GREENWICH, Conn.--(BUSINESS WIRE)-- BharCap Partners, LLC ("BharCap"), a private equity firm focused on the financial services sector, today announced the final closing of its second fund, BharCap Partners Fund II, LP ('Fund II'). Fund II was oversubscribed with $652 million in equity capital commitments, 30% above its $500 million target. BharCap has raised over $1.1 billion of committed equity capital through Fund II and affiliated co-investment vehicles. 'We believe this fundraise demonstrates our differentiated value proposition, the quality and depth of our team and the attractiveness of our sector.' BharCap is led by founding partners Bharath Srikrishnan, Ethan Wang, Jim Rutherfurd, Kevin Becker and Ryan Gean. Bharath Srikrishnan, Co-Founder and Managing Partner, said, 'First and foremost, I would like to thank everyone who has supported us on this four-year journey. We created BharCap because we believe entrepreneurs in our sector would benefit from a new firm with a distinctive approach. We are highly entrepreneurial professionals who are sector specialists. We have unique operational and strategic capabilities. Our 'Entrepreneurs Backing Entrepreneurs' mantra resonates with management teams. We believe this fundraise demonstrates our differentiated value proposition, the quality and depth of our team and the attractiveness of our sector. With 27 professionals and operating advisors and substantial dry powder, we are well positioned to identify and support outstanding management teams.' The fund's closing marks a pivotal moment as BharCap continues to source unique investment opportunities which leverage the firm's longstanding relationships with entrepreneurs. BharCap's Fund II targets management buyouts in asset-light middle-market financial services companies. Our focused sub-sectors include wealth and asset management, insurance distribution and insurance services, financial technology and tech-enabled financial services, and tax, accounting and advisory services. BharCap focuses on companies with recurring revenue, strong profit margins and high free cash flow conversion that we can scale. We seek to invest alongside management teams to capitalize on powerful long-term growth trends, sub-consolidation opportunities in highly fragmented markets and the impact of technological advancement. Fund II and its LP co-investment vehicles typically invest $50 to $300 million in North American companies with EBITDA of $10 to $50 million. Ethan Wang, Co-Founder and Partner, said, 'With our entrepreneur-centric approach and deep sector expertise, we provide the tools that financial services companies need to succeed. We have a robust pipeline of proprietary investment opportunities sourced by our proactive, outbound calling effort. We are excited to originate new investment opportunities, drive continued success for our portfolio companies and create significant value for our limited partners and management teams.' Fund II's investors are a diverse group of limited partners from North America, Europe and Asia, including insurance companies, asset managers, public pension plans, institutional consultants, endowments and foundations, high-net-worth individuals and family offices. Jim Rutherfurd, Co-Founder, Partner and Head of Investor Relations, said, 'We are grateful for and honored by the support from our limited partners, particularly considering the impact of economic and geopolitical uncertainty on the fundraising environment. Our LP base includes some of the most prominent and well-regarded fund investors. Fund II has significant embedded value, and we are highly focused on extending our track record of outstanding asset light financial services investments.' Fund II has invested approximately 30% of the Fund in four portfolio companies in the insurance brokerage, insurance services, payment processing and wealth management sectors. For further inquiries or partnership opportunities, please contact Jim Rutherfurd at jim@ Rede Partners served as placement agent and Kirkland & Ellis served as fund formation legal counsel to BharCap Fund II. About BharCap Partners: BharCap Partners, LLC invests in businesses across the financial services industry including wealth and asset management, insurance distribution and insurance services, financial technology and tech-enabled financial services, and tax, accounting and advisory services. BharCap manages over $2 billion of capital. For more information, please visit
Yahoo
4 hours ago
- Yahoo
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. "We are thrilled to soon launch BYQLOVI, a truly clinically differentiated topical corticosteroid, into a U.S. market that now exceeds 7 million annual ophthalmic surgeries," said Mark L. Baum, Chief Executive Officer of Harrow. "With compelling efficacy, extraordinary safety, and patient‑friendly dosing, BYQLOVI has the potential to shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment." "Harrow's commitment to innovation, patient access, and physician engagement closely aligns with our mission to promote unique clinical advancements that improve patient outcomes," said Erick Co, President and CEO of Formosa Pharmaceuticals. "We are confident that Harrow's leadership in the U.S. eyecare space will ensure BYQLOVI's successful adoption among surgeons and eyecare professionals – and ultimately, better post-surgical experiences for U.S. patients." BYQLOVI, a high-potency ophthalmic corticosteroid formulated using Formosa's proprietary APNT® nanoparticle formulation technology, delivers a highly uniform suspension that minimizes particle setting and provides consistent dosing. Its pharmacologic performance and clinical outcomes position it as a best‑in‑class option for post-operative inflammation and pain. Key highlights of BYQLOVI include: Best-in-Class Pain Relief with 77% and 85%, respectively, of patients in supportive pivotal clinical studies reporting no pain at Day 4 post-surgery; 82% and 87%, respectively, reporting no pain at Day 8 post-surgery. Best-in-Class Inflammation Clearance with 33% and 30%, respectively, of patients in supportive pivotal clinical studies with zero cell counts in the anterior chamber at Day 8 post-surgery. Safety Benefits with only 1.4% of patients experiencing elevated intraocular pressure (IOP), a substantially lower rate compared to other ophthalmic steroids. Best-in-Class Post-Surgical Dosing at 1 drop BID dosing for 14 days on label; without the need for a loading dose and a maintenance phase. About BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05% BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use INDICATIONS AND USAGE BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. CONTRAINDICATIONS BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. WARNINGS AND PRECAUTIONS Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, IOP should be monitored. Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Delayed Healing: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Corneal and Scleral Melting: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. Viral Infections: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. ADVERSE REACTIONS Ocular adverse reactions occurring in ≥ 1% of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure. USE IN SPECIAL POPULATIONS Pregnancy. There are no adequate and well-controlled studies of BYQLOVI administration in pregnant women to inform a drug-associated risk. For additional information about BYQLOVI™, please see the Full Prescribing Information. About Formosa Pharmaceuticals Formosa Pharmaceuticals, Inc. ( is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which BYQLOVI was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. View original content to download multimedia: SOURCE Formosa Pharmaceuticals Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
